Sustainability | February 28, 2026
Lupin tops world pharma and all Indian sectors in S&P ESG rankings
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Under the deal, Quiver will receive an undisclosed advance payment and research support
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
Subscribe To Our Newsletter & Stay Updated
